Sunday, April 13, 2014

The Use of a Trained Dog as a Gait Aid for Clients with Ataxia: A Case Report

The Use of a Trained Dog as a Gait Aid for Clients with Ataxia: A Case Report. Gabriela Abbud, Caroline Janelle, Maria Vocos, Physiotherapy Canada, Volume 66, Number 1 / 2014, 33-35, DOI 10.3138/ptc.2013-17.

Keywords: animal assisted therapy, assistive device, ataxia, gait

Acute colonic pseudo-obstruction after hysterectomy in a patient with Friedreich ataxia

Acute colonic pseudo-obstruction after hysterectomy in a patient with Friedreich ataxia. Cenk Yasa, Ozlem Dural, Funda Gungor Ugurlucan, Ercan Bastu, Omer Demir, Samet Topuz; Archives of Gynecology and Obstetrics, May 2014, Volume 289, Issue 5, pp 1151-1153

Thursday, April 10, 2014

ROLE OF MITOCHONDRIA IN NEURODEGENERATION OF PERIPHERAL NEUROPATHIES.

ROLE OF MITOCHONDRIA IN NEURODEGENERATION OF PERIPHERAL NEUROPATHIES.

Speaker: Aránzazu Bolinches
Date: 11/04/2014 - 13h
Place: Salón de Actos CIPF

Monday, April 7, 2014

AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.

AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.

AAVLife's lead indication is for Friedreich’s Ataxia Cardiomyopathy

The goal is to commence a clinical trial in 2015 to evaluate gene therapy for heart disease associated with Friedreich’s Ataxia. An observational study will be initiated in 2014 as a run-up to treating patients in a Phase I/II study.

Friedreich's Ataxia -- An Effective Gene Therapy In An Animal Model

Friedreich's Ataxia -- An Effective Gene Therapy In An Animal Model. Science 2.0, By News Staff | April 6th 2014

The transfer, via a viral vector, of a normal copy of the gene deficient in patients, allowed to fully and very rapidly cure the heart disease in mice.

As the central nervous system is also a target of AAV vectors, Hélène Puccio and Patrick Aubourg's teams are investigating whether a similar approach using gene therapy could be as effective for the spinal cord and cerebellum as it is for the heart.

AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich’s ataxia to clinic

AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich’s ataxia to clinic. International collaboration advances gene therapy for Friedreich’s ataxia

DOWNINGTOWN, Pa., April 6, 2014 /PRNewswire-USNewswire/ — The Friedreich’s Ataxia Research Alliance (FARA) is pleased to recognize the ground-breaking gene-therapy research of FARA-funded scientist Dr. Hélène Puccio.

FARA Press Release:
International collaboration advances gene therapy for Friedreich’s ataxia; AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich's ataxia to clinic

Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia

Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia. Morgane Perdomini, Brahim Belbellaa, Laurent Monassier, Laurence Reutenauer, Nadia Messaddeq, Nathalie Cartier, Ronald G Crystal, Patrick Aubourg & Hélène Puccio; Nature Medicine (2014) doi:10.1038/nm.3510

KEYWORDS: Cardiac failure, conditional mouse model, adeno-associated virus rh10 vector, establish the preclinical proof of concept, FRDA cardiomyopathy.

Sunday, April 6, 2014

Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo

Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo. Annette Hofer, Natalie Noe, Christin Tischner, Nikolay Kladt, Veronika Lellek, Astrid Schauß and Tina Wenz; Hum. Mol. Genet. (2014) 23 (9): 2400-2415. doi: 10.1093/hmg/ddt631

Gene Expression Profiling of Mitochondrial Oxidative Phosphorylation (OXPHOS) Complex I in Friedreich Ataxia (FRDA) Patients

Gene Expression Profiling of Mitochondrial Oxidative Phosphorylation (OXPHOS) Complex I in Friedreich Ataxia (FRDA) Patients . Salehi MH, Kamalidehghan B, Houshmand M, Yong Meng G, Sadeghizadeh M, Omid Aryani, Shahriar Nafissi; PLoS ONE 9(4): e94069. doi:10.1371/journal.pone.0094069

OPEN ACCESS FULL TEXT PDF